Colgate-Palmolive: Piper Sandler Assumes Neutral, Sets PT at $84

Colgate-Palmolive: Piper Sandler Assumes Neutral, Sets PT at $84

Colgate-Palmolive Company (NYSE: CL) has seen a significant shift in its stock valuation as Piper Sandler has recently assumed a neutral stance, setting a price target of $84. This change in sentiment comes amidst a series of recent developments affecting the company's stock.

During the second quarter of 2025, J. Safra Sarasin Holding AG reduced its holdings in Colgate-Palmolive by 16.6%, now owning approximately $66.65 million worth of shares J. Safra Sarasin Holding AG Has $66.65 Million Stock Holdings in Colgate-Palmolive Company $CL^[1]. This reduction makes Colgate-Palmolive the fund's 25th largest position. The fund owned 733,299 shares after selling 145,570 shares during the period, indicating a 1.2% portfolio allocation to Colgate-Palmolive.

Institutional investors have been actively buying and selling shares of Colgate-Palmolive. For instance, Westend Capital Management LLC raised its holdings by 111.1% in the first quarter, now owning 266 shares valued at $25,000. Cornerstone Planning Group LLC increased its holdings by 1,913.3%, owning 302 shares valued at $28,000. Saudi Central Bank, Ransom Advisory Ltd, and Harel Insurance Investments & Financial Services Ltd also purchased new stakes in the company's shares J. Safra Sarasin Holding AG Has $66.65 Million Stock Holdings in Colgate-Palmolive Company $CL^[1].

Colgate-Palmolive reported better-than-expected earnings for the quarter, with a net margin of 14.55% and a declared quarterly dividend of $0.52 per share, yielding 2.6% J. Safra Sarasin Holding AG Has $66.65 Million Stock Holdings in Colgate-Palmolive Company $CL^[1]. Analysts have mixed ratings for the stock, with seven equities research analysts rating it as a "Buy," three as "Hold," and one as "Sell." The consensus rating is "Moderate Buy" with a target price of $97.27 J. Safra Sarasin Holding AG Has $66.65 Million Stock Holdings in Colgate-Palmolive Company $CL^[1].

Piper Sandler's decision to assume a neutral stance and set a price target of $84 reflects a cautious view on the company's future performance. This move contrasts with the majority of analysts who maintain a "Buy" rating. The shift in sentiment could be attributed to various factors, including recent changes in institutional holdings, earnings reports, and market conditions.

Investors should closely monitor Colgate-Palmolive's future developments, including earnings reports and analyst ratings, to gauge the stock's potential for growth and value. The company's recent earnings and dividend announcements indicate a strong financial position, but the market's reaction to Piper Sandler's neutral stance suggests a need for cautious optimism.